Inhibidores de JAK topicos...

TOPICAL JANUS KINASE ENZYME INHIBITORS

This review paper assessed published evidence on efficacy, safety, and tolerability of topical janus kinase inhibitors (JAKi) in the treatment of cutaneous inflammatory conditions.

Out of 55 potential articles, published in the PubMed database and the Cochrane Library until November 2017, 11 were selected, for a total of 924 patients.

Results of randomized clinical trials (RCTs) indicated moderate improvement in cases of atopic dermatitis and psoriasis; inconsistent data on vitiligo treatment, with improvement observed on the face only, and lack of conclusive data regarding efficacy on alopecia areata.

The authors concluded that topical JAKi represent an interesting therapeutic option for psoriasis, vitiligo, alopecia areata and atopic dermatitis patients, although further studies are needed to corroborate its use in dermatology.

Hosking AM, Juhasz M, Mesinkovska NA. Topical Janus Kinase Inhibitors: A Review of Applications in Dermatology. J Am Acad Dermatol. 2018 Apr 16. pii: S0190-9622(18)30562-0. doi: 10.1016/j.jaad.2018.04.018. [Epub ahead of print]